Clinical trial NCT01722578 - References

Hepatic Encephalopathy — L-ornithine L-aspartate in Overt Hepatic Encephalopathy

Citation(s)

•   Abdo-Francis JM, Pérez-Hernández JL, Hinojosa-Ruiz A, Hernández-Vásquez JR
  [Reduction of hospital stay with the use of L-ornithine L-aspartate (LOLA) in patients with hepatic encephalopathy]. Rev Gastroenterol Mex. 2010;75(2):135-41. Spanish.
•   Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK
  Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology. 2009 Jun;136(7):2159-68. doi: 10.1053/j.gastro.2009.02.050.
•   Ahmad I, Khan AA, Alam A, Dilshad A, Butt AK, Shafqat F, Malik K, Sarwar S
  L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J Coll Physicians Surg Pak. 2008 Nov;18(11):684-7. doi: 11.2008/JCPSP.684687.
•   Als-Nielsen B, Gluud LL, Gluud C
  Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004 May 1;328(7447):1046. Review.
•   Atluri DK, Prakash R, Mullen KD
  Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol. 2011 Sep;1(2):77-86. doi: 10.1016/S0973-6883(11)60126-6. Review.
•   Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN)
  . Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011 Apr;33(7):739-47. doi: 10.1111/j.1365-2036.2011.04590.x. Review.
•   Bongaerts G, Severijnen R, Timmerman H
  Effect of antibiotics, prebiotics and probiotics in treatment for hepatic encephalopathy. Med Hypotheses. 2005;64(1):64-8.
•   Chen MF, Li RC, Chen CH, Gao XC
  [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy]. Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):718-9, 722. Chinese.
•   Ferenci P, Herneth A, Steindl P
  Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis. 1996 Aug;16(3):329-38. Review.
•   Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT
  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002 Mar;35(3):716-21.
•   Goggs R, Serrano S, Szladovits B, Keir I, Ong R, Hughes D
  Clinical investigation of a point-of-care blood ammonia analyzer. Vet Clin Pathol. 2008 Jun;37(2):198-206. doi: 10.1111/j.1939-165X.2008.00024.x.
•   Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW
  Screening of subclinical hepatic encephalopathy. J Hepatol. 2000 May;32(5):748-53.
•   Jiang Q, Jiang XH, Zheng MH, Chen YP
  L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol. 2009 Jan;24(1):9-14. doi: 10.1111/j.1440-1746.2008.05582.x.
•   Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S
  Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997 Jun;25(6):1351-60.
•   Kircheis G, Wettstein M, Dahl Sv, Häussinger D
  Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis. 2002 Dec;17(4):453-62. Review.
•   Lizardi-Cervera J, Almeda P, Guevara L, Uribe M
  Hepatic encephalopathy: a review. Ann Hepatol. 2003 Jul-Sep;2(3):122-30. Review.
•   Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group
  . Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003 Jan;38(1):51-8.
•   Mas A
  Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73 Suppl 1:86-93. Review.
•   Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM
  Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005 Jun 30;46(3):399-407.
•   Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García-Ramos G, Fernández-Zertuche M, Rodríguez-Fragoso L, Uribe M
  Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006 Oct-Dec;5(4):281-8.
•   Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO
  Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut. 2000 Oct;47(4):571-4.
•   Riordan SM, Williams R
  Treatment of hepatic encephalopathy. N Engl J Med. 1997 Aug 14;337(7):473-9. Review.
•   Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF
  L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998 Jun;13(2):147-57.
•   Shawcross D, Jalan R
  Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005 Jan 29-Feb 4;365(9457):431-3.
•   Shawcross DL, Olde Damink SW, Butterworth RF, Jalan R
  Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis. 2005 Sep;20(3):169-79. Review.
•   Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E
  Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 1993 Nov;19(3):424-30.
•   Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J
  Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998 May;28(5):856-64.
•   Uribe M, Morán S, Poo JL, Méndez-Sánchez N, Guevara L, García-Ramos G
  Beneficial effect of carbohydrate maldigestion induced by a disaccharidase inhibitor (AO-128) in the treatment of chronic portal-systemic encephalopathy. A double-blind, randomized, controlled trial. Scand J Gastroenterol. 1998 Oct;33(10):1099-106.

Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial

Details for clinical trial NCT01722578